Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in San Donato Milanese – page 108

2 835 clinical trials in San Donato Milanese, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
San Donato Milanese at a glance
2 835
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 835 trials in San Donato Milanese

Open in trial search

Prostate cancer

Not yet recruiting

Study on the Use of 64Cu-PSMA I&T to Detect Lymph Node Spread in Men with Newly Diagnosed Prostate Cancer Before Surgery

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:64CU-PSMA I&T
  • Sponsor:Curium US LLC

Non-small cell lung cancer

Not yet recruiting

Study of Pembrolizumab, Vibostolimab, and Chemotherapy for Patients with Newly Diagnosed Resectable Stage II-IIIB Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Leiomyosarcoma+5

Not yet recruiting

Study on the Effectiveness and Safety of INT230-6 (Vinblastine Sulfate, Cisplatin) for Adults with Metastatic Soft Tissue Sarcomas

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Intensity Therapeutics Inc.

Systemic lupus erythematosus+1

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel in Patients with Systemic Lupus Erythematosus and Active, Refractory Lupus Nephritis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Novartis Pharma AG

Nervous system disorder+1

Not yet recruiting

Study of KYV-101 Therapy for Patients with Refractory Primary and Secondary Progressive Multiple Sclerosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:KYV-101
  • Sponsor:Kyverna Therapeutics Inc.

Systemic scleroderma

Not yet recruiting

Study comparing rapcabtagene autoleucel and rituximab in patients with severe refractory diffuse cutaneous systemic sclerosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Cardiac arrest

Not yet recruiting

Study on the Safety of Argon and Oxygen Ventilation for Patients Resuscitated from Cardiac Arrest

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Argon
  • Sponsor:Istituto Di Ricerche Farmacologiche Mario Negri

Lung carcinoma cell type unspecified recurrent

Not yet recruiting

Study of Durvalumab with Thoracic Radiotherapy and Chemotherapy for Patients with Extensive Stage Small Cell Lung Cancer After Initial Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Azienda Ospedaliero Universitaria Di Modena

Pulmonary embolism+1

Not yet recruiting

Study on Sulodexide for Preventing Recurrence of Blood Clots in Elderly Patients After First Episode of Deep Vein Thrombosis or Pulmonary Embolism

Registered drug
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Sulodexide
  • Sponsor:Fondazione Arianna Anticoagulazione

Cervical dysplasia+1

Not yet recruiting

Study on Pembrolizumab for Patients with High-Grade HPV-Related Vulvar and Cervical Lesions

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Chronic kidney disease

Not yet recruiting

Study on Finerenone for Slowing Chronic Kidney Disease Progression in Patients Receiving Standard Care

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:The George Institute For Global Health

Study on the Effect of Phosphocreatine Sodium and Sodium Chloride in Patients Treated by Medical Emergency Teams with Conditions like Rapid Breathing or Low Blood Pressure

Not yet recruiting
Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Ospedale San Raffaele S.r.l.

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in San Donato Milanese

What the registry says about research in the country

01 Gastroenterology Research

Leading studies focusing on inflammatory bowel diseases, including investigations of novel treatments for Crohn's Disease and Ulcerative Colitis. Research encompasses both established and experimental therapies aimed at inducing clinical remission.

  • Crohn's Disease Management
  • Ulcerative Colitis Treatments
  • Fecal Incontinence Therapy

Multiple trials evaluating innovative therapeutic approaches for gastrointestinal conditions.

02 Cardiovascular Studies

Comprehensive research into heart conditions, with particular emphasis on hypertrophic cardiomyopathy and heart failure. Studies evaluate new medications and surgical interventions.

  • Heart Failure Management
  • Cardiac Surgery Outcomes
  • Myocardial Infarction Research

Innovative approaches in treating various cardiac conditions using precision medicine techniques.

03 Immunology Research

Groundbreaking studies in hereditary angioedema and chronic urticaria, investigating both preventive treatments and acute attack management strategies.

  • Hereditary Angioedema Treatments
  • Chronic Urticaria Management
  • Pediatric Immunology Studies

Advanced therapeutic options being developed for rare immunological disorders.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.